ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
126.224,74
0,00%
S&P 500
6.083,57
0,36%
US Dollar vs BRL
5,7642
0,04%
Bitcoin
97.722,29
1,19%
Brent Oil
74,695
0,71%
As Melhores Corretoras Online
Registration Strip Icon for tools Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. 60 Degrees Pharmaceuticals Inc (SXTPW)

  7. 60 Degrees Pharmaceuticals Inc (SXTPW) Notícias

SXTPW

60 Degrees Pharmaceuticals (SXTPW)

60 Degrees Pharmaceuticals Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SXTPW
DataHoraFonteTítuloCódigoCompanhia
06/02/202518:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
06/02/202516:07GlobeNewswire Inc.60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
06/02/202512:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
05/02/202511:22GlobeNewswire Inc.60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
30/01/202516:20GlobeNewswire Inc.60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
29/01/202510:00GlobeNewswire Inc.60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
28/01/202510:01GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
24/01/202518:52Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
08/01/202510:02GlobeNewswire Inc.60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) BabesiosisNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
23/12/202410:57GlobeNewswire Inc.Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and PreventionNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
11/12/202410:56GlobeNewswire Inc.60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s HospitalNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
14/11/202416:31GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Third Quarter 2024 ResultsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
14/11/202415:44Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
15/10/202416:46Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
03/10/202410:02GlobeNewswire Inc.60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. LaunchNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
02/10/202411:56Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
01/10/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
19/09/202417:30Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
06/09/202409:59GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
04/09/202409:00GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
28/08/202415:48GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing RequirementsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
14/08/202412:01GlobeNewswire Inc.60 Degrees Pharmaceuticals Announces Second Quarter 2024 ResultsNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
12/08/202410:12GlobeNewswire Inc.60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb StudyNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
06/08/202410:26GlobeNewswire Inc.60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock SplitNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
25/07/202410:02GlobeNewswire Inc.60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade SupportNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
19/07/202409:29GlobeNewswire Inc.60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis StudyNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
09/07/202407:31GlobeNewswire Inc.60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior TreatmentNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
27/06/202408:59GlobeNewswire Inc.First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its KindNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
11/06/202408:59GlobeNewswire Inc.60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute BabesiosisNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
30/05/202408:59GlobeNewswire Inc.Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its KindNASDAQ:SXTPW60 Degrees Pharmaceuticals Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SXTPW

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
AMOB3
Automob Participacoes ON
BOV
TELB4
TELEBRAS PN
BOV
RCSL4
RECRUSUL PN
BOV
RCSL3
RECRUSUL ON
BOV
GOLL4
GOL PN
BOV
COGN3
COGNA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios